Primary Navigation for the CDC Website
CDC en EspaƱol

Division of Foodborne, Bacterial and Mycotic Diseases (DFBMD)


General Information | Technical Information | Additional Information



Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.

Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-1170.

Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority study. Lancet 2005; 266: 1435-42.

Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002: 347; 2020-9.

Ostrosky-Zeichner L, Rex JH, Bennett JE, et al. Deeply invasive candidiasis. Infect Dis Clin North Am 2002; 16: 821-835.

Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20: 485-506.

Pappas PG, Rex JH, Sobel JD, et al. Guidelines for the treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.

Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007: 2007; 883-93.

Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.

Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002: 40; 3551-3557.

Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007: 356; 2472-82.

Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85.

Sobel JD, Faros Force RW, Foxman B, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203-211.

Sobel JD, Ohmit SE, Schuman P, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001; 183: 286-293.

Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961-71.

Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.

For more information, you may also wish to go to the following website:

Back to Top

* Links to non-Federal organizations found at this site are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization Web pages found at these links.

Page last modified: March 27, 2008
Content Source: National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ZVED)

Program Contents

Contact Information

cdc info logo
800-CDC-INFO (232-4636)

TTY: 888-232-6348

In English/en Español-24/7